omega-3 ethyl esters
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
2
Earliest trial started Oct 1, 2010 (NCT01229566)
Timeline
Indications
Approved for
Mechanism of action
AWAT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- akr-963
- tak-085
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06434948 | Phase 2 | Nov 30, 2024 | University of Missouri |
| NCT02839902 | Phase 4 | Dec 15, 2016 | Takeda |
| NCT02824432 | Phase 4 | Jun 30, 2016 | Takeda |
| NCT01229566 | Phase 3 | Oct 1, 2010 | Trygg Pharma, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 2 | 2 | 1 | 2016 |
| Trygg Pharma, Inc. | For profit | 1 | 1 | 1 | 2010 |
| University of Missouri | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1